Veru报告了2b期QUALITY研究维持扩展部分的总体疗效和安全性结果，证明在停止semantic后12周内，安慰剂单药治疗组体重恢复了43%，而Enobosarm单药治疗组体重恢复了46%

--During the Maintenance Period of 12 weeks after discontinuing semaglutide (GLP-1 receptor agonist), placebo group regained 43% of body weight that was previously lost during Phase 2b QUALITY study; on average, enobosarm 3mg significantly reduced body weight regain by 46% and completely prevented fat regain compared to placebo--

--The enobosarm treated groups showed up to 93% greater fat loss and 100% lean mass preservation compared to the placebo group at the end of the study--

--Enobosarm monotherapy had a positive safety profile with essentially no gastrointestinal side effects during the maintenance treatment period--

-- Based on efficacy and safety from Phase 2b QUALITY and Maintenance Extension study:

--Enobosarm 3mg will advance as the proposed oral dose for the Phase 3 clinical program--

--Veru has been granted a meeting with FDA to discuss the Phase 3 clinical program--